Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
SNOA · NASDAQ · Surgical & Medical Instruments & Apparatus
Sonoma Pharmaceuticals (SNOA) · oqro.io/stocks/SNOA · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$0.722−0.0877 (−10.83%)
Close of Nov 20, 2026, vs Nov 19 · end-of-day
No open-market purchase by an insider of Sonoma Pharmaceuticals was filed in the last 90 days. The latest on record was on Mar 13, 2018.
Since 2007, Sonoma Pharmaceuticals insiders reported 66 open-market purchases and 10 sales on Forms 4 and 5, with purchases in 9 different years, most recently 2018.
No open-market sale by an insider of Sonoma Pharmaceuticals (SNOA) was filed with the SEC in the last 90 days.
No trade in Sonoma Pharmaceuticals (SNOA) was disclosed by a member of Congress in the last 12 months.
Sonoma Pharmaceuticals's next results are expected on Feb 8, 2027. The date can move until the company confirms it. Insiders often trade in the weeks right after results.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
−77.9% (−$2.54) from Nov 20, 2025 to Nov 20, 2026 · adjusted daily closes
No disclosed open-market insider trades, politician trades or fund 13F changes in this period.
Adjusted close went from $3.26 on Nov 20, 2025 to $0.722 on Nov 20, 2026 (−77.9%). Disclosed in this range: 0 insider trades, 0 pre-arranged insider sales, 0 Congress trades.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Surgical & Medical Instruments & Apparatus company based in Boulder, Co.
Last 12 months
−77.8%
Market value
$3.65M
S&P 500 +5.7% over the same dates. Prices adjusted for splits and dividends.
Short interest: 67K shares sold short (1.3% of shares outstanding), −38.7% vs the previous count, 1.7 days of normal trading to buy them back. FINRA, as of Oct 30, 2026. Short interest history
Revenue, fiscal 2026
$19.5M
+36.7% vs the year before
Net income, fiscal 2026
−$3.17M
A loss for the year
Shares outstanding
5.06M
As of Nov 10, 2026
Nothing reported yet
New filings show up here as soon as they are processed.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Revenue
$7.17M
+28.0% vs the same quarter a year earlier
Free cash flow, last 12 months
−$2.79M
This quarter −$778K, a year earlier −$645K
Net debt
—
Debt —, cash $4.61M, at Sep 30, 2026
Net income, last 12 months
−$1.8M
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Nov 8, 2018.
Revenue and earnings history, 16 fiscal yearsEarnings dates and the stock's moves
Latest annual report filed Jun 16, 2026, compared with the one filed Jun 17, 2025. Read the filing
We may be involved in legal matters arising in the ordinary course of our business including matters involving proprietary technology. While management believes that such matters are currently insignificant, matters arising in the ordinary course of business for which we are or could become involved in litigation may have a material adverse effect on our business, financial condition or results of comprehensive (loss) income.
Source: SEC EDGAR, Form 10-K filed Jun 16, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Contracts, lobbying and filings
Company reports, price and press
Who holds it
Things to keep in mind
No Schedule 13D or 13G filing on SNOA over the last three years: no investor has reported crossing 5% of its stock in that time.
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
Against the S&P 500 over the year
Since Nov 19, 2025, SNOA is down 78.4% and the index fund is up 4.1%: 82 points behind the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much SNOA moves
Beta 1.5 (1 year vs SPY)
End-of-day prices. These figures describe the past year and say nothing about what comes next. Beta: how much the stock moved, on average, for each 1% move of the S&P 500 fund over 251 trading days (1 = in step with it).
Last results
Nov 8, 2018
More than 30 days ago
Next results, expected
Feb 8, 2027
Purchases after results
74%
48 of 65 insider purchases since 2007 came within 30 days after a results announcement
From Sonoma Pharmaceuticals's own results filings (8-K Item 2.02) and its insiders' Forms 4 and 5. Many companies only let insiders trade in a period after results; OQRO does not know Sonoma Pharmaceuticals's policy and only shows the pattern in the filings. A purchase made long after results, at a company whose insiders usually buy right after them, is marked “Bought outside the usual window”.
Insiders of Sonoma Pharmaceuticals reported 66 open-market purchases and 10 sales since 2007; purchases in 9 different years, most recently 2018.
| Year | Bought | Sold |
|---|---|---|
| 2018 | $24K4×4 trades | — |
| 2017 | $67K18×18 trades | — |
| 2016 | $39K4×4 trades | — |
| 2014 | $11K1×1 trade | — |
| 2013 | $12K1×1 trade | — |
| 2012 | $22K13×13 trades | — |
| 2010 | $47K4×4 trades | $47K1×1 trade |
| 2009 | $983K17×17 trades | $778K8×8 trades |
| 2008 | — | $80K1×1 trade |
| 2007 | $135K4×4 trades | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Off-exchange trading: 55.0% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (9.0% on ATS, 46.0% with other brokers), close to its 26-week average of 54.1%. Weeks of Sep 21 to Oct 16, 2026.
Largest ATS: IBKR ATS (74.9%), VIRTU MATCHIT ATS (3.9%), INTELLIGENT CROSS LLC (3.2%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.
Every annual report has a section where the company's managers explain the year's results (Item 7, Management's discussion and analysis). In this report it runs to about 2,000 words.
The preparation of our consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to exercise its judgment. We exercise considerable judgment with respect to establishing sound accounting policies and in making estimates and assumptions that affect the reported amounts of our assets and liabilities, our recognition of revenues and expenses, and disclosure of commitments and contingencies at the date of the consolidated financial statements. On an ongoing basis, we evaluate our estimates and judgments. Areas in which we exercise significant judgment include, but are not necessarily limited to, our valuation of income taxes. On an ongoing basis, we evaluate our estimates and judgments.
And 1 more heading in the filing.
Source: SEC EDGAR, Form 10-K filed Jun 16, 2026. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.